HCPCS Level II code J7182 designates the per-IU billing unit for recombinant factor VIII (antihemophilic factor, recombinant), branded as NovoEight, used for replacement therapy in patients with hemophilia A. Nationally, this code matters because recombinant clotting factors represent a high-cost, high-impact category of specialty injectable medications that drive pharmacy and infusion expenditures and require accurate coding for dosing-based reimbursement and medical necessity validation.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for J7182, typical sites of service where the product is administered, and the types of benchmarks and policy topics commonly associated with high-cost clotting factor products — including billing unit structure, prior authorization and medical necessity considerations, and payer coverage patterns. The publication also outlines related operational issues such as billing per international unit, inventory and waste reporting practices, and where to look for payer-specific guidance.

This summary is intended for healthcare revenue cycle, pharmacy, and clinical policy audiences seeking a national perspective on coding and administrative considerations for recombinant factor VIII therapy billed under J7182.